PA-EXONE
9.11.2021 14:33:10 CET | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today unveiled the X1 Powder Grip, an ergonomically friendly 2-liter powder container that’s part of an innovative powder management system for the all-new InnoventPro™ metal 3D printer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005475/en/
The global premier of the InnoventPro metal 3D printer featuring the X1 Powder Grip is slated for Formnext 2021, to be held Nov. 16-19 in Frankfurt, Germany. ExOne will have the system on display in Hall 12.0, D69.
The InnoventPro 3L is the world’s most advanced entry-level model for metal binder jetting — designed to take the easy-to-use features of the popular Innovent+ with patented Triple ACT advanced compaction technology and offer them with a bigger build area and the best speed and cutting-edge technology features of ExOne’s production-ready printers, such as the X1 25Pro® and X1 160Pro™.
The X1 Powder Grip is part of a comprehensive new powder management system for the InnoventPro. To load metal powder into the new machine, a user positions two easy-to-use X1 Powder Grip containers, which weigh about 20 pounds each when fully loaded with 316L stainless steel, into a powder hopper at the rear of the machine with an easy quarter-turn. After the powder release valve is opened, a conveyance system lifts the powder hopper from a loading position into the build area for recoating and printing.
The X1 Powder Grip is also designed to be seamlessly used for powder reclamation and reuse with an all-new depowdering station that pairs with the InnoventPro.
What is Binder Jet 3D Printing?
ExOne’s binder jet 3D printing transforms powdered materials – metal, sand or ceramic – into highly dense and functional precision parts at high speeds.
An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. ExOne now delivers high densities of greater than 97% for most metals, in line with Metal Injection Molding or gravity castings.
Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
Learn more about the InnoventPro at exone.com/innoventpro .
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005475/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release
DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 16:15:00 CET | Press release
The trial includes 4,000 credits and four concurrent runs, so a team can generate functional and adversarial suites from its own agent's docs and endpoint, with code optional, and gate CI on evidence-backed verdicts without booking a demo. TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom